Found 150 clinical trials
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures
- 0 views
- 03 Jul, 2025
- 15 locations
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
- 0 views
- 25 Jun, 2025
- 4 locations
Longitudinal Survey of ALK+ Cancer Patients (now called the ALK Life Study)
The primary objective of this survey is to collect data from ALK+ lung cancer patients (and their caregivers) to improve:
<ul>- 0 views
- 27 Feb, 2025
- 1 location
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations (DETERMINE)
cancer known as a METex14 skipping mutation.Investigators now wish to find out if it will be useful in treating patients with other cancer types which have the same mutation or other specific
- 0 views
- 03 Jul, 2025
- 16 locations
![Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma](/media/imagery/217282.svg)
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. [89Zr
- 0 views
- 25 Jun, 2025
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portionwill enroll first followed by the Phase 2 portion. Each cycle of treatment = 28<br>days.Subjects will receive alectinib twice daily. Those in the Phase 1b portion willreceive alectinib alone. Those in Phase 2 Arm A …
- 0 views
- 10 Jan, 2025
- 2 locations
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
- 0 views
- 10 Jan, 2025
- 6 locations
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
- 0 views
- 10 Jan, 2025
- 2 locations
Upper Extremity Exercise Capacity Of Breast Cancer
Breast cancer is one of the most common cancers among women worldwide, with an incidence rate of up to 16%. Although survival can be improved with early diagnosis and more effective therapies
- 0 views
- 14 Mar, 2025
- 1 location
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary
- 0 views
- 10 Jan, 2025
- 4 locations